Ligand Third Quarter 2026 Earnings Call - LIGAND PHARMACEUTICALS INC

Explicit Guidance:

• Full-Year 2026 Adjusted Diluted EPS: Raised to $9.50 – $9.75 per share (previously $9.00 – $9.50).
• Full-Year 2026 Revenue Guidance (Reaffirmed):
  • Royalty Revenue: $225 – $250 million.
  • Total Revenue: $270 – $310 million.
  • Cap-to-Sell Revenue: $35 – $40 million.
  • Contract Revenue: $10 – $20 million.
• FY2026 EPS Contribution from ZOMA: Expected to be $0.50 in 2026 and $1.50 in 2027.
• Core Cash Operating Expenses (2026): On track at approximately $50 million (down from $92M in 2022).
• Long-Term Growth (2022–Mid-2026): Anticipated CAGR of 34% for royalty revenue and 41% for adjusted EPS.
• Capital Deployment Rate: Approximately $200 million per year is expected to sustain growth through the mid-2030s; deployment rate accelerating.
• Q4 Revenue Weighting: Expect 2026 revenue to be heavily weighted to Q4 due to full ZOMA quarter inclusion and tiered royalty rate escalations.

Business-Segment Outlook:

• Portfolio Scale: Portfolio expanded to >200 assets (commercial, clinical, preclinical) following ZOMA acquisition and new investments.
• Key Commercial Assets:
  • Filspari: Largest royalty asset ($16.8M Q3 est., +85% YoY); growth expected to continue in FSGS and IGAN; Chugai submitting for Japan approval.
  • ZOMA Assets: Added $12.3M royalty revenue in 11 weeks post-close (July 14); includes Ojemda, Vibismo, and MyPlypha.
  • Raijunia: 16th key commercial program; tiered royalty (low double-digit to high teens) in Europe, Middle East, and Africa (EU/UK approved for pediatric myopia).
• Pipeline Catalysts (Through 2027):
  • Anticipate up to seven pivotal trial readouts.
  • Palvella (Cuturin rapamycin): FDA PDUFA date February 28, 2027 (Microcystic Lymphatic Malformations); potential commercial launch in US H1 2027; Royalty rate 8% – 9.8%.
  • Takeda Programs (ZOMA):
    • Mezogidamab (ITP/IG): Phase 3 results late 2027/early 2028; Peak sales >$1.5B; Potential royalty >$30M.
    • Osovarpamore (MDD): Phase 3 results H2 2027; Peak sales $500M–$1.8B; Potential royalty up to $80M.
    • Velixibet (PSC/PBC): PBC top-line results Q1 2027; Peak sales >$1B; Potential royalty >$45M.
    • Ojemda (Pediatric Glioma): Phase 3 results 2027; Potential peak royalty ~$25M.
  • Orchestra (AVIM): BackBeat Global Pivotal Trial results expected Q2 2027.
  • Avancel (CAR-T): AVC201 (AML) Phase 1b ongoing; platform royalty (mid-single to low double-digit) on all future pipeline assets.

Market and Competitive Outlook:

• Investment Pipeline: Reviewed >180 opportunities in 2026; 115 CDAs signed (60% conversion rate); 6 investments closed (including ZOMA, Avancel, Raijunia, Zerion, Agenis, Primrose, SideNexus).
• Deal Flow: Activity level "upticking" with two new deal leads added; aiming to maintain high selectivity (approx. 5% close rate).
• Competition: Acknowledged high competition in commercial royalty space; strategy relies on complex deals, special situations, and superior diligence to achieve alpha (targeting returns often in low to high teens or >20%).
• Pricing Dynamics: Tiered royalty structures anticipated to step up as partner sales grow, typically realized later in the year.

Macro / Industry Outlook:

• Economic/Market View: Management expresses "high confidence" in royalty revenue approaching the mid-to-high end of Q4 guidance ($64M–$89M implied).
• Accounting/Reporting Changes: Shift to earlier reporting schedule through 2027 due to financial royalty asset accounting; estimates based on sell-side consensus will be trued up in subsequent quarters.
• Long-Term Framework Update: A revised five-year outlook (replacing the 23% royalty CAGR target) will be presented at the December 8th Investor Day, factoring in ZOMA, Filspari approval, and Palvella NDA acceptance.
• FX/Regulatory: No specific FX or macro headwinds detailed beyond standard biopharma regulatory timelines; Palvella approval path considered clear following FDA interactions.

Strategic Initiatives:

• ZOMA Acquisition (Completed July 14): Added 3 commercial assets and >100 pipeline programs; integrated two employees (one full-time, one consultant).
• Cost Synergies: ZOMA cash operating expense run rate reduced from >$25M to ~$5M annually (synergies "tad better than expected").
• New Investments (2026):
  • Raijunia (Santen): 100% interest in European/EMEA payment rights; $23M upfront.
  • Avancel (Advent Cell): Up to $47M financing (royalty + equity) for CAR-T platform; milestone-tranche structure.
• Platform Expansion: Systematic portfolio management system implemented to proactively identify opportunities and increase yield; deal team expanded.
• Asset Revitalization: Sotiklestat rights revitalized via new investment by Perceptive Advisors (Misdrow Bio); MyGand entitled to share of royalties/milestones.

Risks and Headwinds to Outlook:

• Clinical/Binary Risk: No guarantee of positive outcomes for the seven anticipated pivotal readouts; development carries inherent "binary risk."
• Timing Uncertainty: Primary driver of revenue variance; dependent on partner reporting schedules, capital material sales timing, and shifting milestone dates.
• Estimation Variance: Q3 royalty revenue estimates (based on consensus) may differ from actual partner reports; adjustments occur in the following quarter (e.g., Travier, Filspari).
• Regulatory Risk: US regulatory skepticism regarding Raijunia in myopia (adcom upcoming) poses no immediate read-across risk to EU/UK, but monitored.
• Guidance Caveats: Management does not rely on clinical/regulatory event outcomes in setting guidance; upside exists if milestones are achieved.

Management Tone on the Future:

• Confidence Level: "Extremely catalyst-rich period"; describes current state as the "most catalyst-rich" in nearly 40-year history.
• Tone: Highly positive regarding portfolio diversification and capital deployment capability ($750M deployable capital); expresses "strong confidence" in sustaining growth into the next decade.
• Hedges: Maintains a "measured" approach on top-line guidance (Q4) to account for timing variability and pending partner reports, despite strong confidence in the upper range.
• Changes: Reaffirms long-term strategy unchanged by ZOMA acquisition; emphasizes "disciplined" capital allocation and selective deal-making.

Miscellaneous:

• Share Count: Convertible notes (0% coupon due 2031, $700M) have warrants with strike prices ~$524; dilution at $400 share price estimated at ~3%.
• Balance Sheet: Cash/cash equivalents/short-term investments: ~$450 million (down from $734M due to ZOMA acquisition and convertible note issuance); total deployable capital ~$750 million including equity holdings and credit facility.
• Financial Results: Q3 Royalty Revenue $70.3M (+51% YoY); Adjusted EPS $2.67; Core cash opex run rate on track at $50M.